Full-Time

Senior Product Marketing Manager

Omnicell

Omnicell

1,001-5,000 employees

Medication management and pharmacy automation platform

No salary listed

Boston, MA, USA + 1 more

More locations: Austin, TX, USA

Hybrid

Remote or hybrid; up to 25% travel (domestic and international)

Category
Product (1)
Required Skills
Market Research
Requirements
  • Bachelor's degree in marketing, business, healthcare administration, or related field
  • Minimum 5-8 years of experience in product marketing with at least 5 years focused on healthcare technology, pharmacy solutions, medical devices, or capital equipment
  • Demonstrated success developing and executing go-to-market strategies that drove measurable revenue growth and market share gains in B2B technology or capital equipment environments
  • Proven ability to lead both strategic planning and hands-on execution, managing multiple initiatives simultaneously in fast-paced, dynamic markets
  • Strong portfolio of marketing deliverables including positioning documents, sales tools, campaign materials, and customer-facing content
  • Deep understanding of medication adherence challenges, pharmacy operations (retail, hospital, long-term care, mail-order), medication packaging workflows, and pharmacy automation technologies
  • Expertise in marketing capital equipment and B2B technology solutions including go-to-market planning, competitive positioning, product launches, demand generation, and customer lifecycle marketing
  • Strong presence with ability to communicate complex value propositions clearly and compellingly to diverse audiences including C-suite executives, pharmacy directors, operations leaders, and clinical stakeholders
  • Proven cross-functional leadership and stakeholder management skills with ability to influence without authority and drive alignment across matrixed organizations
  • Data-driven decision maker proficient in marketing analytics, customer segmentation, sales funnel analysis, and using insights to optimize strategies and demonstrate business impact
Responsibilities
  • Lead cross-functional GTM strategy and execution for new product introductions and commercial campaigns across Med Adherence
  • Develop differentiated positioning and messaging based on market insights, customer segmentation, and competitive intelligence
  • Partner with Product Management, Sales, and Clinical teams to define and communicate value propositions tailored to providers, payers, and pharmacies
  • Create sales enablement tools, training materials, and playbooks to drive revenue growth and market share
  • Analyze campaign performance, customer feedback, and sales metrics to optimize marketing efforts and influence roadmap priorities
  • Support pricing and packaging strategy in collaboration with Finance and Product teams to maximize commercial outcomes
  • Represent marketing in key customer meetings, tradeshows, and executive briefings to reinforce value messaging and gather market feedback
Desired Qualifications
  • MBA or advanced degree in business, healthcare administration, or related field
  • Direct experience marketing medication adherence solutions, pharmacy automation, packaging systems, or medication management technologies
  • Background working with or marketing to health systems, retail pharmacies, long-term care facilities, or mail-order pharmacy operations
  • Experience marketing both hardware/capital equipment and software/SaaS solutions in integrated product portfolios
  • Understanding of pharmacy regulations, USP standards, medication synchronization programs, and adherence quality measures
  • Track record successfully launching complex technology solutions requiring installation, implementation, and ongoing service support

Omnicell provides medication management solutions and adherence tools for health systems and pharmacies, combining pharmacy automation devices with cloud-based software to automate dispensing, manage inventory, and support patient adherence. The products mix hardware and a cloud platform that coordinates dispensing, inventory control, and clinical data through dashboards and analytics. Compared with competitors, Omnicell emphasizes a cloud-first software approach with a clear path to software-as-a-service and a hybrid direct-plus-partner sales model for end-to-end pharmacy automation and data services. Its goal is to realize the Autonomous Pharmacy by using automation and intelligent services to improve pharmacy care and patient outcomes while building recurring revenue.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Mountain View, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Titan XT targets $2.5B replacement cycle with H2 2026 shipments.
  • ARR hits $680-700M by 2026 end, nearing 50% of revenue.
  • Rick Couldry's May 2026 hire accelerates clinical adoption of OmniSphere.

What critics are saying

  • Swisslog erodes XT Series share via Epic integration in 6-12 months.
  • Nvidia-BD Pyxis analytics slash OmniSphere conversions in 12-24 months.
  • 25% tariffs raise IV costs $12M, drop margins below 40% in 2026.

What makes Omnicell unique

  • Omnicell automates medication management with XR2, IVX Workflow, and XT Series cabinets.
  • OmniSphere cloud platform delivers predictive analytics and real-time inventory visibility.
  • Titan XT enables autonomous pharmacy through AI-driven dispensing and interoperability.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Omnicell who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 5th, 2026
Omnicell's Titan XT cabinet launch divides analysts on $1.3B revenue outlook

Omnicell's analyst narrative centres on its Titan XT cabinet system and a potential hospital replacement cycle, though opinions diverge sharply on timing. The modelled fair value holds at $57.43 amid mixed price target revisions. BofA, Benchmark and KeyBanc have taken bullish stances, with KeyBanc upgrading to Overweight at $60, citing competitive wins and a cabinet refresh cycle. Conversely, Piper Sandler cut its target by $14, flagging execution and timing risks around the same Titan XT story. Omnicell issued Q1 2026 revenue guidance of $300 million to $310 million and full-year guidance of $1.215 billion to $1.255 billion. The company has launched Titan XT in the US, with international rollout expected later in 2026.

Yahoo Finance
Feb 28th, 2026
Omnicell targets $2.4B revenue by 2031 with shift to AI-driven pharmacy automation

Omnicell, Inc. is transitioning from hardware-driven revenue to a software and services model, aiming to double revenue from $1.18 billion to $2.4 billion by 2031, according to a bullish thesis on Danny's Substack. The company is expanding through strategic acquisitions like ANiGENT and developing its "Autonomous Pharmacy" vision using AI and robotics. The healthcare automation firm benefits from high switching costs, over 900 patents and a large installed base. Recurring revenue is approaching 50% of total revenue, with margins expected to expand from low teens to mid-20s. Bulls believe the market currently undervalues Omnicell as a hardware vendor, creating potential for significant rerating as it shifts towards healthcare IT, with shares trading at $38.61 as of 18 February.

Yahoo Finance
Feb 2nd, 2026
Omnicell beats Q3 revenue estimates by 5%, stock surges 64% since earnings report

Omnicell, a provider of medication management automation and adherence tools for healthcare systems and pharmacies, reported third-quarter revenues of $310.6 million, up 10% year on year and exceeding analysts' expectations by 5%. The company also beat earnings per share estimates. "We are pleased with the strong financial performance delivered in the third quarter," said Randall Lipps, Omnicell's chairman, president and chief executive officer. The stock has risen 64% since reporting results and currently trades at $48.49. The healthcare technology for providers sector faces mixed conditions, with opportunities from AI-driven tools and government digitisation incentives offset by challenges including long sales cycles, slow adoption rates, and tightening hospital budgets. The four companies tracked in this sector reported satisfactory third-quarter results overall, though share prices have declined 5.3% on average since earnings.

Specialty Pharmacy Continuum
Aug 18th, 2025
Texas Children's Hospital Adopts RFID for OR Med Management

This May, medication and supply management technology company Omnicell launched a new radio frequency identification (RFID)-enabled device to manage medications in the operating room.

StreetInsider
Mar 24th, 2025
Omnicell (OMCL) appoints Perry Genova as CTO

Omnicell, Inc. (Nasdaq: OMCL), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025.